Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Trends Biochem Sci. 2022 Aug;47(8):673-688. doi: 10.1016/j.tibs.2022.03.018. Epub 2022 Apr 27.
Rapid phenotypic antimicrobial susceptibility testing (AST) requires the enrichment of live bacteria from patient samples, which is particularly challenging in the context of life-threatening bloodstream infections (BSIs) due to low bacterial titers. Over two decades, an extensive array of pathogen-specific biomolecules has been identified to capture live bacteria. The prevailing biomolecules are immune proteins of the complement system, antibodies, aptamers, phage proteins, and antimicrobial peptides. These biomolecules differ by their binder generation technologies and exhibit highly variable specificities, ranging from bacterial strains to most pathogenic bacteria. Here, we summarize how these diverse biomolecules were identified, list examples of successfully reported capture assays, and provide an outlook on the use of nanobodies raised against conserved surface-accessible proteins as promising biomolecules for pathogen capture.
快速表型抗菌药物敏感性检测(AST)需要从患者样本中富集活细菌,由于细菌滴度低,这在危及生命的血流感染(BSI)情况下特别具有挑战性。二十多年来,已经鉴定出了大量的病原体特异性生物分子来捕获活细菌。流行的生物分子是补体系统的免疫蛋白、抗体、适体、噬菌体蛋白和抗菌肽。这些生物分子因其结合物生成技术的不同而具有高度可变的特异性,从细菌株到大多数致病菌。在这里,我们总结了这些不同的生物分子是如何被鉴定出来的,列出了成功报道的捕获检测的例子,并展望了针对保守表面可及蛋白产生的纳米抗体作为有前途的病原体捕获生物分子的应用。